Melanie Ufkin

miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia

Melanie Ufkin, Sarah Peterson, Xuehui Yang et al. · Leukemia Research · 2014 · 76 citations · Full text

Hematological Malignancy, Tumor Biology, Erbb Pathway +12

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, John N. Allan, Jon Arnason et al. · Blood · 2019 · 55 citations

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sabarish Ayyappan, Won Seog Kim, Tae Min Kim et al. · Blood · 2023 · 44 citations

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Nature Cancer · 2025 · 33 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Won-Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Blood · 2022 · 28 citations